JP2015517466A5 - - Google Patents

Download PDF

Info

Publication number
JP2015517466A5
JP2015517466A5 JP2015510380A JP2015510380A JP2015517466A5 JP 2015517466 A5 JP2015517466 A5 JP 2015517466A5 JP 2015510380 A JP2015510380 A JP 2015510380A JP 2015510380 A JP2015510380 A JP 2015510380A JP 2015517466 A5 JP2015517466 A5 JP 2015517466A5
Authority
JP
Japan
Prior art keywords
rnai agent
composition
kras
strand
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015510380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517466A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/038847 external-priority patent/WO2013166004A2/en
Publication of JP2015517466A publication Critical patent/JP2015517466A/ja
Publication of JP2015517466A5 publication Critical patent/JP2015517466A5/ja
Pending legal-status Critical Current

Links

JP2015510380A 2012-05-02 2013-04-30 Ｋｒａｓ関連疾患を処置するための有機組成物 Pending JP2015517466A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261641588P 2012-05-02 2012-05-02
US61/641,588 2012-05-02
PCT/US2013/038847 WO2013166004A2 (en) 2012-05-02 2013-04-30 Organic compositions to treat kras-related diseases

Publications (2)

Publication Number Publication Date
JP2015517466A JP2015517466A (ja) 2015-06-22
JP2015517466A5 true JP2015517466A5 (enExample) 2016-06-23

Family

ID=48366565

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015510380A Pending JP2015517466A (ja) 2012-05-02 2013-04-30 Ｋｒａｓ関連疾患を処置するための有機組成物

Country Status (12)

Country Link
US (3) US20150238515A1 (enExample)
EP (3) EP2844757A2 (enExample)
JP (1) JP2015517466A (enExample)
KR (1) KR20150004414A (enExample)
CN (2) CN104583406A (enExample)
AU (5) AU2013256471A1 (enExample)
BR (1) BR112014027337A2 (enExample)
CA (2) CA2872304C (enExample)
EA (1) EA201492004A1 (enExample)
HK (1) HK1206387A1 (enExample)
MX (1) MX2014013367A (enExample)
WO (1) WO2013166004A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201620525A (zh) * 2014-03-14 2016-06-16 波士頓生醫公司 使ｋ－ｒａｓ靜默之非對稱干擾ｒｎａ組成物及其使用方法
US10278991B2 (en) 2014-05-14 2019-05-07 Targimmune Therapeutics Ag Polyethyleneimine polyethyleneglycol vectors
US11180759B2 (en) * 2016-01-19 2021-11-23 The University Of North Carolina At Chapel Hill Methods and compositions using RNA interference and antisense oligonucleotides for inhibition of KRAS
US10858656B2 (en) * 2016-04-01 2020-12-08 Avidity Biosciences, Inc. KRAS nucleic acids and uses thereof
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
KR102543645B1 (ko) * 2016-07-20 2023-06-16 주식회사 지씨지놈 유전성 발달장애 진단용 조성물 및 이의 용도
CN118638787A (zh) 2017-12-06 2024-09-13 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
CN113993521A (zh) * 2019-06-05 2022-01-28 南方研究院 基于噻拉滨和噻拉滨前药的治疗
US12146139B2 (en) * 2019-11-14 2024-11-19 The Board Of Regents Of The University Of Oklahoma Oligonucleotide interference treatments of prostate cancer
TW202144572A (zh) 2020-03-19 2021-12-01 美商亞維代堤生物科學公司 治療臉肩胛肱骨肌肉失養症之組合物及方法
JP7839554B2 (ja) * 2020-04-07 2026-04-02 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Ｋｒａｓの阻害のためのｒｎａ干渉およびアンチセンスオリゴヌクレオチドを使用する方法および組成物
WO2023034537A1 (en) * 2021-09-02 2023-03-09 Molecular Axiom, Llc Compositions and methods for modulating kras expression
EP4401792A4 (en) 2021-09-16 2025-12-03 Avidity Biosciences Inc COMPOSITIONS AND METHODS OF TREATMENT OF FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY
JP2026503133A (ja) * 2023-01-18 2026-01-27 モレキュラー アクシオム エルエルシー Ｋｒａｓ発現を調節するための組成物及びその使用
KR20250155026A (ko) * 2023-02-22 2025-10-29 알타미라 테라퓨틱스 아게 질병 치료를 위한 kras 억제용 조성물 및 방법
WO2026026715A1 (zh) * 2024-07-31 2026-02-05 前沿生物药业(南京)股份有限公司 一种用于抑制KRAS基因表达的siRNA及其修饰物与应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
JP2003526367A (ja) 2000-03-16 2003-09-09 ジェネティカ インコーポレイテッド Ｒｎａ干渉の方法とｒｎａ干渉組成物
US6680068B2 (en) 2000-07-06 2004-01-20 The General Hospital Corporation Drug delivery formulations and targeting
WO2002100435A1 (en) 2001-06-11 2002-12-19 Centre Hospitalier Universitaire De Montreal Compositions and methods for enhancing nucleic acid transfer into cells
WO2003015757A1 (en) 2001-08-16 2003-02-27 The Trustees Of The University Of Pennsylvania Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
EP1658304A4 (en) 2002-09-28 2009-01-14 Massachusetts Inst Technology THERAPY ANTIGRIPPALE
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
WO2004048545A2 (en) 2002-11-26 2004-06-10 University Of Massachusetts DELIVERY OF siRNAs______________________________________________
US20040208921A1 (en) 2003-01-14 2004-10-21 Ho Rodney J. Y. Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
AU2004257373B2 (en) 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
CN1845993B (zh) 2003-08-28 2010-06-23 诺瓦提斯公司 具有平端和3＇修饰的干扰rna双链体
EP1675949A2 (en) * 2003-10-23 2006-07-05 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF NOGO AND NOGO RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1714970A1 (en) * 2005-04-22 2006-10-25 Universität des Saarlandes Use of inhibitors of RNAse A-family enzymes for stabilizing oligonucleotides having RNA interfering activity
EP1948674A4 (en) 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF
ES2556128T3 (es) 2006-03-23 2016-01-13 Roche Innovation Center Copenhagen A/S ARN interfiriente pequeño internamente segmentado
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
EP2081949B1 (en) * 2006-09-22 2014-12-10 GE Healthcare Dharmacon, Inc. Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
EP2121925A2 (en) * 2007-03-02 2009-11-25 MDRNA, Inc. Nucleic acid compounds for inhibiting ras gene expression and uses thereof
NZ580712A (en) 2007-05-22 2011-12-22 Marina Biotech Inc Hydroxymethyl substituted rna oligonucleotides and rna complexes containing acyclic monomers
EP2190995A2 (en) * 2007-09-18 2010-06-02 Intradigm Corporation Compositions comprising k-ras sirna and methods of use
WO2009062199A1 (en) * 2007-11-09 2009-05-14 Fox Chase Cancer Center EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
US9006191B2 (en) 2007-12-27 2015-04-14 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering RNA
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
US20110218334A1 (en) * 2008-07-11 2011-09-08 Alnylam Pharmaceuticals, Inc. PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS
JP6010458B2 (ja) * 2009-04-03 2016-10-19 ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 非対称二本鎖ｒｎａによる特異的阻害のための、方法および組成物
WO2010115202A2 (en) * 2009-04-03 2010-10-07 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
WO2011110671A2 (en) * 2010-03-12 2011-09-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pharmaceutical composition for the treatment of chlamydial infection

Similar Documents

Publication Publication Date Title
JP2014525435A5 (enExample)
JP7728923B2 (ja) 筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート
JP2015503608A5 (enExample)
JP2023093644A (ja) アンジオテンシノーゲンの発現を調節するための化合物及び方法
JP7118063B2 (ja) 筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート
JP2016511256A5 (enExample)
JP2013525332A5 (enExample)
JP2013514321A5 (enExample)
JP2022528725A (ja) 筋ジストロフィーを治療するための組成物
JP7291418B2 (ja) Ｐｃｓｋ９を標的としたアンチセンス核酸
JP2018512060A5 (enExample)
JP2019504112A5 (enExample)
HRP20201200T1 (hr) OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK
JP2023539341A (ja) Ｄｕｘ４阻害剤およびその使用方法
JP2014518612A5 (enExample)
US9080175B2 (en) Organic compositions to treat Beta-ENaC-related diseases
JP2011517676A5 (enExample)
JP2016513976A5 (enExample)
US20200190517A1 (en) Organic compositions to treat epas1-related diseases
JP2019503199A5 (enExample)
JP2021526017A (ja) 筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート
AU2016204832A1 (en) Organic compositions to treat KRAS-related diseases
JP2021521794A (ja) 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート
CN108138180A (zh) 用于治疗皮肤t细胞淋巴瘤（ctcl）的mir-155抑制剂
TW202300647A (zh) 用於治療多囊腎病之組成物